Objective: Despite the increasing number of studies reporting results of stereo-electroencephalography (SEEG)-guided radiofrequency-thermocoagulation (SEEGguided RF-TC) in the treatment of patients with drug-resistant focal epilepsy, the exact efficacy of this approach remains unclear. The seizure-freedom rate varies greatly across studies and the factors associated with efficacy have not been formally investigated. Methods: All prospective or retrospective studies reporting efficacy and/or safety of SEEG-guided RF-TC in patients with drug-resistant focal epilepsy were included. The primary outcome was the seizure-free rate 1 year after the procedure. Secondary outcomes were (1) the responder rate 1 year after the procedure and (2) the proportion of patients with permanent neurologic deficit 1 year after the procedure. Each outcome was assessed in all patients and in 4 groups of patients defined by the etiology of epilepsy. Each outcome was pooled using inverse variance weighting, logit transformation of proportion, and a randomeffects model. Results: No prospective study was identified and a total of 6 retrospective studies, reporting efficacy and safety data of 296 patients, were included. The pooled rate of permanent neurologic deficit was 2.5% (95% confidence interval [CI] 1.2%-5.3%), without heterogeneity across studies. In contrast, both the seizure-free and responder rates varied greatly across studies, and statistical heterogeneity was high. The pooled seizure-free and responder rates were 23% (95% CI 8%-50%) and 58% (95% CI 36%-77%), respectively. Both for the seizure-free and responder rates, the greatest efficacy was observed in patients with periventricular nodular heterotopia and the lowest in patients with normal magnetic resonance imaging (MRI) findings. Significance: SEEG-guided RF-TC is a safe procedure with low risk of complications. In contrast, the level of evidence regarding its efficacy remains low. Better identification of factors associated with seizure outcome are needed.
| INTRODUCTION
Stereotactic lesioning has progressively emerged as an important surgical treatment in focal epilepsy, especially as an alternative to conventional surgery in mesial temporal lobe epilepsy 1 or in patients with focal lesions that are not eligible for surgical resection, such as periventricular nodular heterotopias. 2 Several stereotactic procedures have thus been developed over the past years, including laser interstitial thermotherapy (LiTT), 3 radiosurgery, 4 high-intensity focal ultrasound (HIFU), 5 and stereo-electroencephalography-guided radiofrequency-thermocoagulation (SEEGguided RF-TC). 6 Coupling stereotactic lesioning through RF-TC to intracranial EEG recording by means of common electrodes allows the selective lesioning of limited volumes that target the seizure-onset zone. Moreover, this approach might limit the risk of surgical complications by reducing the number of invasive stereotactic procedures. 7 However, despite encouraging results, seizure outcomes following SEEGguided RF-TC remain unclear, with a seizure-freedom rate varying from 4% to 71% across studies. Furthermore, the predictive factors associated with postoperative outcome remain in question. Specifically, although some studies suggest that specific patient groups may achieve better outcomes, especially those with periventricular nodular heterotopias, the impact of the underlying etiology on the success rate of SEEG-guided RF-TC has been poorly investigated to date.
To address these issues, we performed a systematic review and meta-analysis of studies reporting efficacy and safety outcomes following SEEG-guided RF-TC. Our primary objectives were to evaluate the seizure-freedom rate, the responder rate, and the risk of permanent neurologic deficit after a follow-up of 1 year. We then investigated whether efficacy outcomes were influenced by the underlying etiology.
| METHODS
The study was performed according to the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines (see Table S1 for the PRISMA checklist). 8, 9 2.1 | Study search and selection
| Eligibility criteria
To qualify for inclusion, a study had to meet all of the following criteria: (1) prospective or retrospective study reporting efficacy and/or safety of SEEG-guided RF-TC in patients with drug-resistant focal epilepsy; (2) sample size >3 patients; (3) provides the number of seizure-free patients and/or responders (patients with at least 50% reduction in seizure frequency as compared with the preprocedure period); and (4) provides the number of adverse events and number of patients with permanent neurologic deficit following SEEG-guided RF-TC. Detailed information concerning the exact number of patients achieving each of these outcomes was mandatory to identify overlapping populations across publications from the same group. No restrictions based on language or publication status were imposed.
| Study search
A detailed search was made on 3 electronic databases-MEDLINE, Cochrane (CENTRAL), and the Web of Science-for the period from 1960 to December 31, 2017 
| Data abstraction
After removal of duplicates, all titles and abstracts were screened. The studies that did not fulfill the eligibility criteria were excluded and the full text of the others was then assessed in detail. Studies that fulfilled all inclusion criteria were included in the meta-analysis. A first reviewer (PB)
Key Points
• As indicated in the eligibility criteria, specific attention was paid to identify overlapping populations across publications from the same group. In the case of a study-reporting results with a partial overlap with a previous study, its data were extracted and adjusted to exclude the patients already included in the previous study. When an overlap was strongly suspected in a study but the quality of the published data did not allow the exclusion of duplicates, that study was excluded from the meta-analysis.
Validity and risk of bias of eligible studies was assessed using the Oxford Centre for Evidence-based Medicine classification system. 10 Publication bias was sought using funnel plots, where asymmetry was analyzed using linear regression.
| End points and statistical methods

| End points
The primary outcome was the seizure-free rate 1 year after the procedure. Secondary outcomes were (1) the responder rate 1 year after the procedure and (2) the proportion of patients with permanent neurologic deficit 1 year after the procedure.
Each outcome was assessed in all patients and in 4 groups of patients defined by the etiology of epilepsy: (1) hippocampal sclerosis (HS), (2) periventricular nodular heterotopias (PNH), (3) focal cortical dysplasia or tuberous sclerosis (FCD), and (4) patients with normal MRI findings.
| Variability estimates
Each outcome was polled using inverse variance weighting and logit transformation of proportion. Clopper-Pearson confidence intervals were used for individual studies. The random-effects model was preferred because of anticipated heterogeneity across studies. Heterogeneity was assessed by the I 2 statistic, which is independent of the number of studies and quantifies heterogeneity on a scale of 0%-100%. 11 Significant heterogeneity was considered to be present if I² was 50% or more. 12 The summary measures were the effect summary value and 95% confidence intervals (CIs). Because of the lack of consistent etiology groups across all included studies, we were unable to calculate relative risk ratios. Results were indirectly compared among studies with 95% CIs and forest plots. In order to investigate the potential impact on efficacy of the methodology used during the RF-TC procedure, we analyzed the relationship between the seizure-free rate 1 year after the procedure and the mean number of RF-TC reported in each study using a meta-regression approach with a mixed-effects model for the estimation.
All meta-analyses were performed using R (GNU GPL v2) and package meta.
| RESULTS
| Results of the study search
The search strategy identified 239 publications and a single ongoing study (https://clinicaltrials.gov/ct2/show/NCT028866 50 13 ). Following the review of all abstracts, 224 studies were excluded due to irrelevance or duplicate publication. The remaining 15 studies ( Figure 1 ) were examined in detail (Table S2) , and after exclusion of duplicates and case reports, 6 remaining studies were including in the final analysis. A partial overlap of data was detected between 2 studies, with 14 patients with periventricular nodular heterotopias reported in Cossu et al 14 also included in Mirandola et al. 15 The data of these 14 patients were removed from those extracted from Cossu et al (Table 1) .
| Study design and population characteristics in eligible trials
The main characteristics and results of the 6 studies included in the analysis are summarized in Table 1 . All 6 studies were retrospective, noncomparative case series. The seizure-free rate, the responder rate, and the number of patients with permanent neurologic deficit were available in all included studies. According to the Oxford Centre for Evidence-based Medicine classification, all studies reached a level of evidence 2c (Table 2) . A total of 296 patients, including 128 female patients (43%), were examined ( Table 1 The RF-TC procedure used bipolar stimulation in all studies. All studies but one (Mirandola et al) 15 provided information about the number of RF-TCs. At study level, the mean ± SD number of RF-TCs performed in each patient ranged from 5 ± 4.3 to 12.5 ± 9.9. At patient level, the number of RF-TCs ranged from 1 to 71. However, more detailed information about the number of RF-TCs with respect to etiology of epilepsy, efficacy outcomes, or safety outcome was not available at the individual patient level.
As shown in Figure S1 , the funnel plots provided no evidence of publication bias. However, these analyses were limited by the small number of studies.
| Efficacy outcomes
| Seizure freedom
The seizure-free rate 1 year after RF-TC varied greatly across studies from 4% to 71%, and heterogeneity across . Using a random-effects model, the pooled seizure-free rate was 23% (95% CI 8%-50%; Figure 2A ). At study level, the seizure-free rate was not affected by the number of RF-TCs (P = 0.75 by meta-regression).
| Responder rate
As observed for the seizure-free rate, heterogeneity was also very high for the responder rate (I 2 = 86% [95% CI 72%-93%]). Using a random-effects model, the pooled responder rate was 58% (95% CI 36%-77%; Figure 2B ).
| Subgroup analyses
To further investigate the very high heterogeneity observed for the seizure-free and for responder rates, we examined both outcomes in a subgroup analysis. Considering that the efficacy of RF-TC might depend upon the underlying epileptogenic lesion, patients were separated into 4 groups based on etiology: hippocampal sclerosis (n = 39 in 3 studies), PNH (n = 23 in 3 studies), FCD or tuberous sclerosis (n = 67 in 3 studies), and normal MRI (n = 125 in 4 studies).
As shown in Figure 3 , both for the seizure-free and responder rates, the greatest efficacy was observed in 
| Safety outcome
The proportion of patients with permanent neurologic deficit 1 year after the procedure was similar across studies, with no significant heterogeneity detected (I 2 = 0% [95% CI 0%-32%]). Using a fixed-effects model, the pooled rate of permanent neurologic deficit was 2.5% (CI 1.2%-5.3%; Figure 2C ). Permanent neurologic deficit 1 year after the procedure was reported in a total of 5 patients in 3 studies. In 4 patients, all of whom underwent coagulation within the primary motor area, a motor deficit was sustained: ankle paresis (n = 2), nondominant hand paresis (n = 1), and distal dominant arm paresis (n = 1). 16, 17 The remaining patient had permanent hypoesthesia of the right thumb. 18 
T A B L E 2 Validity of included studies
| DISCUSSION
Despite the increasing number of studies reporting results of SEEG-guided RF-TC in the treatment of patients with drug-resistant focal epilepsy, the exact efficacy of this approach remains unclear. Although some groups have suggested that this stereotactic procedure might be of particular interest in patients with focal lesions that are noneligible for cortical resection, such as PNH, the impact of the underlying etiology on the efficacy of the procedure remains to be formally investigated. The present systematic review and meta-analysis, which aimed at addressing this issue, demonstrated that: (1) in absence of prospective studies, the level of evidence of available data remains low; (2) the pooled seizure-free and responder rates following SEEG-guided RF-TC are 23% and 58%, respectively; (3) the risk of complications following the procedure is low, with 2.5% of patients having permanent neurologic deficit; (4) heterogeneity of seizure outcomes is very high across studies and is not only related to the underlying etiology of epilepsy; (5) better identification of factors associated efficacy of the procedure on seizure control is needed. Our study has several limitations. The analysis of funnel plots provided no evidence of publication bias for any of the 3 main outcomes (ie, seizure freedom, responder rate, and permanent neurologic deficit). However, these results should be interpreted with caution, because due to the small number of studies, the possibility of publication bias could not be formally excluded. Although a prospective study is ongoing (NCT02886650), 13 all included studies used a retrospective design. Accordingly, the level of evidence of these studies and of the meta-analysis of their results remains low. In addition, the results were driven mostly by 2 studies, 14, 16 which represented 80% of the whole cohort. Of greatest importance, heterogeneity was very high for both seizure-free and responder rates. Despite the use of a random-effects model for both outcomes, this heterogeneity limits the interpretability of the pooled results. Although we suspected that this heterogeneity in the whole cohort may have been driven primarily by the underlying lesion, our results do not confirm this hypothesis, since heterogeneity remained high in the sub-group analysis according to etiology. The only exception was the responder rate in PNH, which demonstrates consistent results across studies. In contrast, one might suggest that the heterogeneity reflected variation in the management of SEEG-guided RF-TC across centers. These variations were unlikely to be related to technical differences between the centers, as the technique described in the material and methods section of each study was remarkably similar to the original description. 6 In contrast, target selection was not based on the same criteria across studies. Some centers only targeted contacts showing evidence of either spike-wave discharges or low amplitude fast pattern at the onset of the seizure, whereas others targeted greater cortical volume with the aim of lesioning a larger part of the epileptogenic network. The quality of the available data did not allow us to investigate the exact impact of these different aspects on the outcomes. Whether the efficacy of RF-TC might be improved with integration of a functional brain 16 and whether the modalities utilized for target selection and the number of RF-TCs within a single center were strictly similar over a period of several years might be an open question. One might thus speculate that increasing experience in the management of the procedure might result in progressive evolution of these aspects over time. Tackling these important issues would require either a dedicated prospective study or a meta-analysis on individual patient data. The seizure-free rate was 23% (CI 8%-50%) after SEEGguided RF-TC. This result is inferior to the success rate usually observed following conventional resective surgery. 21, 22 For patients with hippocampal sclerosis, the observed seizure-free rate was 25%; as such, SEEG-guided RF-TC should not be proposed as a curative option, given that anterior temporal lobectomy results in seizure freedom in up to 80% of cases. 23 In contrast, results of SEEG-guided RF-TC in PNH, which are rarely accessible to surgical resection, 24, 25 are encouraging with 38% (CI 6%-84%) of seizurefree patients and 83% (CI 57%-96%) of responders. SEEGguided RF-TC might thus be considered as the most effective treatment for drug-resistant epilepsy related to PNH. Overall, these data reinforce the view that SEEG-guided RF-TC should not be considered as an alternative to cortical resection but might represent a feasible interventional option in patients who are not eligible for epilepsy surgery. In contrast, how RF-TC compares to LiTT remains unclear. Several clinical studies evaluating LiTT have been published over the past years. Most of them reported the seizure outcome following LiTT in patients with MTLE. [26] [27] [28] [29] Although the seizure-free rate varied across the series, the results following LiTT might be close to those reported in patients who undergo selective hippocampo-amygdalectomy. 26, 28, 29 These data suggest that LiTT might be superior to RF-TC for this indication. Some studies have also reported encouraging results of LiTT in other types of epilepsies, especially in patients with PNH 30, 31 and focal cortical dysplasia. 26, 27 In these patients, a greater lesion volume is possible with LiTT, which may be associated with better seizure outcome than RF-TC; however, this remains to be investigated. In addition, this potential limitation of RF-TC should be balanced by the advantage of having a one-stage procedure during which a lesion can be performed directly on the basis of SEEG data.
The pooled complication rate of SEEG-guided RF-TC was low (2.5%. CI 1.2%-5.3%), with homogeneous results across studies. This safety profile might be related in part to the coupling of stereotactic lesioning through RF-TC to SEEG recording. Using direct electric stimulation, patients can thus benefit from extensive functional mapping. Accordingly, it is noteworthy that the majority of neurologic deficits reported in the included studies were expected, the RF-TC having been deliberately performed in eloquent cortex because of its crucial involvement in the epileptic network. 16 Only one patient had an unexpected deficit after the RF-TC, but with few consequences on daily life (hypoesthesia of the right thumb). 18 Bleeding occurred after SEEG-guided RF-TC in a single patient. This bleeding was considered as unrelated to the RF-TC, 18 suggesting that RF-TC does not increase the bleeding risk of SEEG.
| CONCLUSION
***SEEG-guided RF-TC, is a safe stereotactic invasive treatment of drug-resistant focal epilepsy, which may be considered when conventional resective surgery is not feasible. Patients with PNH demonstrate the best outcome, whereas efficacy is poorest in those with normal MRI. However, the level of evidence regarding SEEGguided RF-TC efficacy remains low, and better identification of factors associated with the seizure outcome is still needed.
